Semaglutide's Weight Loss Effects in Obesity
ConditionObesity
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorBeijing Chao Yang Hospital
About this trial
This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.
Eligibility criteria
Qualifiers
Age 18-60 years
BMI ≥ 30 kg/m²
At least one self-reported unsuccessful attempt at lifestyle weight loss
Disqualifiers
Weight change (self-reported) > 5% in the past 3 months prior to screening
Use of any medication for obesity indication in the past 3 months prior to screening.
Use of antidiabetic medications in the past 3 months, or HbA1c ≥ 6.5%, or a history of Type 1 or Type 2 diabetes.
Use of immunosuppressants, corticosteroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering medications, and/or other gastrointestinal motility drugs in the past 3 months prior to screening.
Trial design
Treatments tested in this trial
- Semaglutide Subcutaneous Injection
Treatment groups
56 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov